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bp = base pair; CC = CC-chemokine; CCR5 = CC_chemokine receptor 5; GCA = giant cell arteritis; HLA = human leukocyte antigen; ICAM =
intercellular adhesion molecule; IL = interleukin; IL-1 RN = IL-1 receptor antagonist; PMR = polymyalgia rheumatica; RA = rheumatoid arthritis;
RANTES = regulated upon activation, normal T cell expressed and presumably secreted; TNF = tumor necrosis factor.
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Introduction
Giant cell arteritis (GCA) (temporal arteritis) constitutes a
common vasculitic syndrome in European and North
American countries that affects large and middle-sized
blood vessels, with a predisposition to the cranial arteries,
in people generally over 50 years of age [1].
Polymyalgia rheumatica (PMR) is also a common syn-
drome in people over the age of 50. The symptoms are
pain, aching, and morning stiffness involving the neck, the
shoulder girdle, and the hip girdle, which are generally
associated with an elevated erythrocyte sedimentation
rate [2]. PMR and GCA are related diseases, as PMR may
be the presenting manifestation of GCA and is found in up
to 50% of patients with GCA [2]. However, PMR is some-
times an isolated condition unrelated to GCA. The possi-
bility of a genetic influence on susceptibility to GCA was
initially supported by reports of cases of GCA among first-
degree relatives.
Human leukocyte antigens in susceptibility to
GCA and PMR
Human leukocyte antigen class II genes
GCA is the best example of an association between vas-
culitis and genes that lie within the HLA class II region [3].
Most studies have shown an association with HLA-
DRB1*04 alleles [4]. In addition, the risk of visual complica-
tions is also associated with HLA-DRB1*04 alleles [1].
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Giant cell arteritis (GCA) (temporal arteritis) and polymyalgia rheumatica (PMR) are common,
frequently related conditions in people generally over 50 years of age. Most studies have shown an
association of GCA with HLA-DRB1*04 alleles. As regards isolated PMR, however, the HLA class II
genetic susceptibility varies from one population to another. Besides associations with HLA, tumor
necrosis factor appears to influence susceptibility to both conditions. Genetic polymorphisms have
also been considered to be important candidates as factors of susceptibility to GCA and PMR. In this
regard, gene polymorphisms for ICAM-1 (intercellular adhesion molecule 1), RANTES (regulated upon
activation, normal T cell expressed, and presumably secreted), and interleukin (IL)-1 receptor
antagonist seem to play a role in the pathogenesis of GCA and PMR in some populations. However,
additional studies are required to clarify the genetic influence on susceptibility to these conditions.
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Unlike PMR in the context of GCA, which is mostly associ-
ated with HLA-DRB1*04, the susceptibility to isolated
PMR associated with HLA class II genes varies from one
population to another [4]. Relapses of PMR, however, have
been found to be significantly more common in patients
who have the HLA-DRB1*04 allele, and particularly in
those carrying the HLA-DRB1*0401 allele [5]. A lack of
homozygosity of the shared epitope in GCA has been
reported in northwestern Spain [4] and Rochester, Min-
nesota [6]. This finding contrasts with observations regard-
ing rheumatoid arthritis (RA), where homozygosity of the
shared epitope is generally associated with additional risk
of a more severe disease. These findings suggest that the
pathology seen in GCA may be due to antigenic cross-
reactivity or hypersensitivity after exposure and response to
an infectious agent [4]. This mechanism would be consis-
tent with some epidemiological data and the observed sea-
sonal variation in disease onset. However, other, unknown,
predisposing factors in the elderly may be implicated in the
pathogenesis of these conditions.
Role of TNF in susceptibility to GCA and PMR
Apart from HLA-class II genes, it is likely that other genetic
factors may contribute to the susceptibility to these condi-
tions, particularly those factors involved in inflammation.
GCA and PMR share evidence of an inflammatory
process. However, concentrations of tumor necrosis
factor (TNF)-a have not been found to be elevated in
either condition. In northwestern Spain, GCA and PMR
are associated with different TNF microsatellite polymor-
phisms. GCA is strongly associated with the allele encod-
ing the TNF-a2 microsatellite. This association is largely
independent of the association of GCA with HLA class II
genes. A negative association with TNF-a10 was also
found. In contrast, in patients with isolated PMR, there is a
positive association with TNF-b3, which is also indepen-
dent of the HLA class II association with isolated PMR,
and a negative association with TNF-d4 [7]. Thus, TNF
and HLA associations appear to be able to influence sus-
ceptibility to these conditions independently of each other.
Influence of genetic polymorphisms in the
susceptibility to GCA and PMR
ICAM-1 biallelic polymorphisms
Genetic polymorphisms in endothelial-cell adhesion mole-
cules have also been considered to be important candidate
susceptibility factors for GCA and PMR. The intercellular
adhesion molecule (ICAM-1) is a member of the
immunoglobulin-like superfamily group of adhesion mole-
cules and is a ligand for b2 integrins present on leukocytes.
It plays an important role in interactions between endothe-
lial cells and leukocytes during inflammation. Expression of
ICAM-1 on vascular endothelial cells can be significantly
increased in the presence of mediators, which include
lipopolysaccharide and cytokines such as interleukin-1 (IL-
1), TNFa, and interferon-g. In biopsies of temporal arteries
from GCA patients, ICAM-1 is highly expressed in the
adventitial microvessels and neovessels within inflamma-
tory infiltrates [8], and changes in concentrations of circu-
lating soluble ICAM-1 have been correlated with disease
activity in GCA [9]. Two polymorphisms of the coding
region have been identified for ICAM-1: G or R at codon
241 (exon 4) and K or E at codon 469 (exon 6) [10]. In
Italian patients with PMR and GCA, a higher frequency of
the allele R at codon 241 of ICAM-1 has recently been
reported [11]. In these patients, an association between
polymorphism at codon 241 and an increased risk of
relapses in PMR was also observed. However, unlike the
findings in most series, GCA was not associated with HLA-
DRB1*04 in that particular region of northern Italy. In north-
western Spain, in contrast, where susceptibility to GCA
has been associated with HLA-DRB1*04 [4], no evidence
was found of an interaction between HLA-DRB1*04 and
polymorphisms of ICAM-1. Thus, in that particular region,
ICAM-1 polymorphisms are not genetic risk factors affect-
ing the susceptibility and severity of GCA [12].
Polymorphism in the human RANTES gene promoter
The cytokine RANTES is a potent chemotactic factor for
monocytes, CD45RO+ memory T cells, basophils,
eosinophils, and mast cells. Increased serum levels of this
CC chemokine have been found in untreated PMR [13].
Hajeer et al have recently reported a novel polymorphism
(G or A) in the human RANTES gene promoter at position
–403 [14]. Because of this finding, an analysis of the poly-
morphism at this position was performed in patients with
isolated PMR and with biopsy-proven GCA unassociated
with PMR. The frequency of allele A was significantly
higher in patients with PMR – but not in patients with GCA
– than in controls [15]. This observation suggests that the
presence of the RANTES allele A at position –403 may
make a person susceptible to the development of PMR.
CCR5 polymorphism
RANTES is secreted by T lymphocytes, platelets, and syn-
ovial fibroblasts. After interaction with the CC chemokine
receptor 5 (CCR5), it activates memory T cells and mono-
cytes, which are the predominant cells in the synovial
tissue of patients with PMR [16]. The chemokine receptor
CCR5 is encoded by the CMKBR5 gene located on the
p21.3 region of human chromosome 3, and is the major
coreceptor for the macrophage-tropic strains of HIV-1. A
32-nucleotide deletion (D32) in one or both alleles of the
CCR5 gene has been observed [17,18]. This 32-bp dele-
tion within the coding region results in a frame shift,
because of which this gene variant yields a protein
product — a nonfunctional receptor — that is biologically
inactive [17,18]. In patients homozygous for CCR5D32,
the concentration of RANTES secreted by their lympho-
cytes is 5–10 times that found in patients homozygous for
CCR5 [19]. Chemokines are suggested to be critical for
establishment of inflammatory processes in autoimmuneArthritis Research    Vol 3 No 3 Gonzalez-Gay
diseases such as RA. In a series of 673 patients with RA,
none had the homozygous CCR5D32 genotype, com-
pared with a frequency of 0.009 in a group of 815 con-
trols [20]. However, two other studies have not confirmed
the association of CCR5 with RA [21,22]. To assess
whether this 32-bp deletion might play a role in PMR, Sal-
varani et al examined the CCR5 genotype in 88 patients
with PMR in whom RA was excluded, and in 87 controls
[23]. Those workers found that the allele and genotype
frequencies of CCR5D32 in patients with PMR and
healthy controls did not differ significantly. They also found
that the 32-bp deletion from the CCR5 receptor was not
associated with any particular feature of the disease or
with a different frequency of relapses. Thus, the 32-bp
deletion of the CCR5 receptor does not seem to be impli-
cated in the pathogenesis of PMR.
Influence of the IL-1 receptor antagonist gene
The IL-1 receptor antagonist (IL-1 RN) gene is located
on chromosome 2, in close proximity to the IL-1A and
IL-1B genes. Several polymorphic sites have been
described for this gene, including a variable number of
86-base-pair tandem repeats within its second intron
[24]. Allele 2 of this polymorphism was associated with
increased production of IL-1 RN by monocytes and with
higher plasma concentrations. It has also been associ-
ated with severity of the disease in systemic lupus ery-
thematosus, ulcerative colitis, and alopecia areata.
Boiardi and colleagues recently reported a significant
association between susceptibility to PMR and the IL-1
RN*2 allele, particularly in the homozygous state [25].
However, they found no associations between IL-1 RN
biallelic gene polymorphism and relapses of the disease
or duration of corticosteroid therapy.
Conclusion
Although a genetic influence in the pathogenesis of GCA
and PMR does exist, additional studies in different popula-
tions are required to clarify the pathogenesis of these
common and frequently associated conditions. Moreover,
it will be clinically useful to search for genetic markers that
may predict the severity of disease in both conditions.
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